Dihydrolipoic acid inhibits 15-lipoxygenase-dependent lipid peroxidation.
The potential antioxidant effects of the hydrophobic therapeutic agent lipoic acid (LA) and of its reduced form dihydrolipoic acid (DHLA) on the peroxidation of either linoleic acid or human non-HDL fraction catalyzed by soybean 15-lipoxygenase (SLO) and rabbit reticulocyte 15-lipoxygenase (RR15-LOX) were investigated. DHLA, but not LA, did inhibit SLO-dependent lipid peroxidation, showing an IC(50) of 15 microM with linoleic acid and 5 microM with the non-HDL fraction. In specific experiments performed with linoleic acid, inhibition of SLO activity by DHLA was irreversible and of a complete, noncompetitive type. In comparison with DHLA, the well-known lipoxygenase inhibitor nordihydroguaiaretic acid and the nonspecific iron reductant sodium dithionite inhibited SLO-dependent linoleic acid peroxidation with an IC(50) of 4 and 100 microM, respectively, while the hydrophilic thiol N-acetylcysteine, albeit possessing iron-reducing and radical-scavenging properties, was ineffective. Remarkably, DHLA, but not LA, was also able to inhibit the peroxidation of linoleic acid and of the non-HDL fraction catalyzed by RR15-LOX with an IC(50) of, respectively, 10 and 5 microM. Finally, DHLA, but once again not LA, could readily reduce simple ferric ions and scavenge efficiently the stable free radical 1,1-diphenyl-2-pycrylhydrazyl in ethanol; DHLA was considerably less effective against 2,2'-azobis(2-amidinopropane) dihydrochloride-mediated, peroxyl radical-induced non-HDL peroxidation, showing an IC(50) of 850 microM. Thus, DHLA, at therapeutically relevant concentrations, can counteract 15-lipoxygenase-dependent lipid peroxidation; this antioxidant effect may stem primarily from reduction of the active ferric 15-lipoxygenase form to the inactive ferrous state after DHLA-enzyme hydrophobic interaction and, possibly, from scavenging of fatty acid peroxyl radicals formed during lipoperoxidative processes. Inhibition of 15-lipoxygenase oxidative activity by DHLA could occur in the clinical setting, eventually resulting in specific antioxidant and antiatherogenic effects.
Lapenna
Domenico
D
Dipartimento di Medicina e Scienze dell'Invecchiamento and Centro di Scienze dell'Invecchiamento-Fondazione Universita' G. d'Annunzio, Chieti, Italy. piersd@tiscalinet.it
Ciofani
Giuliano
G
Pierdomenico
Sante Donato
SD
Giamberardino
Maria Adele
MA
Cuccurullo
Franco
F
D000111:Acetylcysteine / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001093:Arachidonate 15-Lipoxygenase / Q000378:metabolism*; D004227:Dithionite / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D019787:Linoleic Acid / Q000737:chemistry / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D016859:Lipoxygenase Inhibitors; D009637:Masoprocol / Q000494:pharmacology; D011817:Rabbits; D012156:Reticulocytes / Q000201:enzymology*; D013025:Glycine max / Q000201:enzymology*; D008063:Thioctic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*
D000975:Antioxidants; D016166:Free Radical Scavengers; D005609:Free Radicals; D016859:Lipoxygenase Inhibitors; D004227:Dithionite; D008063:Thioctic Acid; D009637:Masoprocol; C015144:dihydrolipoic acid; D019787:Linoleic Acid; D001093:Arachidonate 15-Lipoxygenase; D000111:Acetylcysteine